HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12-15, 2026. About Bio-Rad Bio-Ra. ...

Core Viewpoint - Bio-Rad Laboratories, Inc. will report its financial results for Q3 2025 on October 29, 2025, after market close [1] Financial Reporting - The financial results will be discussed in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) on the same day [1] - Participants can join the call by dialing (800) 715-9871 within the U.S. or (646) 307-1963 from outside the U.S. [1]

Core Insights - Bio-Rad Laboratories, Inc. is identified as one of the most oversold healthcare stocks in 2025, yet it continues to enhance its product portfolio and market presence [1][5] Group 1: Growth Drivers - The droplet digital PCR (ddPCR) platform, particularly the QX600 system, is a key growth driver for the company, with expectations of mid-single-digit revenue growth in 2025 [2] - The acquisition of Stilla Technologies aims to enhance ddPCR capabilities and facilitate entry into new molecular testing markets [2] Group 2: Product Launches - Bio-Rad has launched several new products to strengthen its diagnostics and research offerings, including the EZ-Check Salmonella spp. Kit, StarBright dyes for spectral flow cytometry, and the XP-Design Assay Salmonella Serotyping solution [3] - In bioprocess chromatography, the company expanded its offerings with Nuvia wPrime 2A media and Foresight Pro prepacked columns, supporting scalable biomolecule purification and GMP-ready biotherapeutic production [4] Group 3: Market Performance - Despite challenges in the U.S. academic and government sectors, Bio-Rad is experiencing improved performance in international markets, particularly in Japan and Korea [5] - The company reported strong Q2 results driven by chromatography and consumables, with plans for a capital markets day in spring 2026 to outline further growth strategies [5]

Core Insights - Bio-Rad Laboratories reported strong Q2 2025 financial results, with adjusted earnings per share (non-GAAP) of $2.61, exceeding the analyst consensus of $1.73, and non-GAAP revenue of $651.6 million, surpassing the expectation of $615.2 million [1][5][10] - Despite the revenue growth of 2.1% year-over-year, both GAAP and non-GAAP gross margins declined, indicating ongoing margin pressures amid industry challenges [1][5][11] Financial Performance - Adjusted EPS (Non-GAAP) for Q2 2025 was $2.61, down 16.1% from $3.11 in Q2 2024 [2] - Non-GAAP revenue reached $651.6 million, a 2.1% increase from $638.5 million in Q2 2024 [2] - Non-GAAP operating margin decreased to 13.6% from 16.7% in Q2 2024 [2] - Free cash flow (Non-GAAP) was $70.8 million, up from $55.4 million in Q2 2024 [2] Segment Performance - The Clinical Diagnostics segment reported net sales of $388.8 million, remaining flat compared to the same period in 2024, impacted by reimbursement cuts in China [7] - Life Science revenue increased by 4.9% in Q2 2025, driven by demand for process chromatography products and food safety products [6] - Ongoing tariff impacts accounted for approximately 130 basis points in non-GAAP operating margin for FY2025 [7] Strategic Focus - The company emphasizes innovation through R&D, product portfolio expansion, and strategic acquisitions as key to its success [4] - Recent acquisition of Stilla Technologies enhances Bio-Rad's digital PCR portfolio, supporting genetic material detection [8] - Management remains open to pursuing larger acquisitions and has accelerated share repurchases, spending $242.1 million in the first half of 2025 [9] Future Outlook - Management raised its non-GAAP revenue growth outlook for FY2025 to around 0% to 1% and increased non-GAAP operating margin guidance to 12.0% to 13.0% [10] - Key areas to monitor include trends in gross and operating margins, changes in China affecting both segments, and U.S. academic funding impacts on laboratory instrument sales [11]